person · Reporting owner

SPRINGER TIMOTHY A

Disclosed activity across 4 companies

Tapewire entity: 39790
SEC CIK: 0001055624

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cartesian Therapeutics, Inc.RNAC · Entity 6015	Director · 10% owner	January 02, 2026	January 06, 2026
Tectonic Therapeutic, Inc.TECX · Entity 5328	Director · 10% owner	June 09, 2026	June 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cartesian Therapeutics, Inc.

Report date January 02, 2026 · Filed January 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	8,646,285	Reported balance After 2026-01-02 transaction · row 1 1 source row Row 1 · 2026-01-02 · Grant · Acquired 2,600 · Balance 8,646,285 F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.76 · Expires 2036-01-01	Direct	7,800	Reported balance After 2026-01-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-01-02 · Grant · Acquired 7,800 · Balance 7,800
Common StockSEC Table I · non-derivative	IndirectBy wife	330,695	Reported balance Holding disclosure · report date 2026-01-02 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 330,695
Common StockSEC Table I · non-derivative	IndirectSee Footnote	656,513	Reported balance Holding disclosure · report date 2026-01-02 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 656,513 F2: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027.

F2: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.

Tectonic Therapeutic, Inc.

Report date June 09, 2026 · Filed June 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.56 · Expires 2036-06-08	Direct	10,200	Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-09 · Grant · Acquired 10,200 · Balance 10,200 F1: The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date.

Filing footnotes · ownership attribution and instrument terms

F1: The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Morphic Holding, Inc.

Report date August 16, 2024 · Filed August 20, 2024

Section 16 reporting ended · disclosed 2024-08-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-08-16 transaction · row 1 1 source row Row 1 · 2024-08-16 · Other · Disposed 4,608,052 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.
Common StockSEC Table I · non-derivative	IndirectSee TAS Partners LLC	Reported balance After 2024-08-16 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2024-08-16 · Other · Disposed 2,768,893 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F3: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares.
Common StockSEC Table I · non-derivative	IndirectBy Spouse	Reported balance After 2024-08-16 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2024-08-16 · Other · Disposed 42,873 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.76 · Expires 2029-04-11	Direct	Reported balance After 2024-08-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-08-16 · Disposition to issuer · Disposed 4,288 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2029-06-26	Direct	Reported balance After 2024-08-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-08-16 · Disposition to issuer · Disposed 24,000 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.72 · Expires 2029-12-05	Direct	Reported balance After 2024-08-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-08-16 · Disposition to issuer · Disposed 90,000 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.96 · Expires 2030-06-18	Direct	Reported balance After 2024-08-16 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-08-16 · Disposition to issuer · Disposed 12,000 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.79 · Expires 2031-06-16	Direct	Reported balance After 2024-08-16 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-08-16 · Disposition to issuer · Disposed 9,996 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.49 · Expires 2032-06-08	Direct	Reported balance After 2024-08-16 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2024-08-16 · Disposition to issuer · Disposed 17,550 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.47 · Expires 2033-05-31	Direct	Reported balance After 2024-08-16 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2024-08-16 · Disposition to issuer · Disposed 12,535 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.52 · Expires 2034-06-03	Direct	Reported balance After 2024-08-16 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2024-08-16 · Disposition to issuer · Disposed 23,168 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F6: The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.

F3: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares.

F4: The Company Stock Option ("Option") is fully vested.

F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof.

F6: The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date.

Scholar Rock Holding Corp

Report date December 10, 2019 · Filed December 12, 2019

Section 16 reporting ended · disclosed 2019-12-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,376,567	Reported balance After 2019-12-10 transaction · row 1 1 source row Row 1 · 2019-12-10 · Gift · Disposed 296,000 · Balance 2,376,567 F1: Represents shares of the Company's common stock transfered as a gift for no consideration to the Institute of Protein Innovation, a not-for-profit research institution.
Common StockSEC Table I · non-derivative	IndirectBy TAS Partners, LLC	580,855	Reported balance Holding disclosure · report date 2019-12-10 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 580,855 F2: Timothy Springer is the Managing Member of TAS Partners LLC.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of the Company's common stock transfered as a gift for no consideration to the Institute of Protein Innovation, a not-for-profit research institution.

F2: Timothy Springer is the Managing Member of TAS Partners LLC.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 25, 2021 Filed May 26, 2021 23:02 UTC	Morphic Holding, Inc. MORF · Entity 88114	PurchaseCommon Stock	8,441	$46.11	$389,225.48	Disclosure SEC source: 0001209191-21-036038 · doc4.xml · nonDerivative · entry 5 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By TAS Partners LLC Disclosed balance after: 812,314 F6 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $46.04 to $46.32 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares. Read SEC document
May 25, 2021 Filed May 26, 2021 23:02 UTC	Morphic Holding, Inc. MORF · Entity 88114	PurchaseCommon Stock	56,559	$45.83	$2,592,155.53	Disclosure SEC source: 0001209191-21-036038 · doc4.xml · nonDerivative · entry 4 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By TAS Partners LLC Disclosed balance after: 803,873 F5 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $45.04 to $46.0317 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares. Read SEC document
May 25, 2021 Filed May 26, 2021 21:21 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	383,830	$3.55	$1,362,097.52	Disclosure SEC source: 0001453687-21-000076 · wf-form4_162206406933869.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 18,228,257 F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $3.40 to $3.65. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held by TAS Partners LLC. The Reporting Person is the managing member of TAS Partners LLC. The Reporting Person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
May 24, 2021 Filed May 26, 2021 23:02 UTC	Morphic Holding, Inc. MORF · Entity 88114	PurchaseCommon Stock	7,550	$47.10	$355,586.13	Disclosure SEC source: 0001209191-21-036038 · doc4.xml · nonDerivative · entry 3 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By TAS Partners LLC Disclosed balance after: 747,314 F4 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $46.98 to $47.33 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares. Read SEC document
May 24, 2021 Filed May 26, 2021 23:02 UTC	Morphic Holding, Inc. MORF · Entity 88114	PurchaseCommon Stock	27,426	$46.54	$1,276,491.06	Disclosure SEC source: 0001209191-21-036038 · doc4.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By TAS Partners LLC Disclosed balance after: 739,764 F3 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $45.98 to $46.97 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares. Read SEC document
May 24, 2021 Filed May 26, 2021 23:02 UTC	Morphic Holding, Inc. MORF · Entity 88114	PurchaseCommon Stock	5,024	$45.43	$228,234.29	Disclosure SEC source: 0001209191-21-036038 · doc4.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By TAS Partners LLC Disclosed balance after: 712,338 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $44.98 to $45.955 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares. Read SEC document
May 24, 2021 Filed May 26, 2021 21:21 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	590,000	$3.38	$1,992,076.00	Disclosure SEC source: 0001453687-21-000076 · wf-form4_162206406933869.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 17,844,427 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $3.19 to $3.51. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held by TAS Partners LLC. The Reporting Person is the managing member of TAS Partners LLC. The Reporting Person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
May 21, 2021 Filed May 25, 2021 23:03 UTC	Morphic Holding, Inc. MORF · Entity 88114	PurchaseCommon Stock	232,295	$45.50	$10,569,422.50	Disclosure SEC source: 0001209191-21-035787 · doc4.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By TAS Partners LLC Disclosed balance after: 707,314 F1 · ownership.nature: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares. Read SEC document
May 21, 2021 Filed May 25, 2021 20:27 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	2,773,479	$3.19	$8,847,398.01	Disclosure SEC source: 0001453687-21-000072 · wf-form4_162197444136325.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 17,254,427 F1 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
March 30, 2021 Filed Apr 1, 2021 22:33 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $4.01	$0.00	Disclosure SEC source: 0001453687-21-000048 · wf-form4_161731638281612.xml · derivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-03-29 F1 · derivative.exercise_date: This option vests in full on March 30, 2022. Read SEC document
March 05, 2021 Filed Mar 9, 2021 00:12 UTC	Morphic Holding, Inc. MORF · Entity 88114	PurchaseCommon Stock	100,000	$70.00	$7,000,000.00	Disclosure SEC source: 0001209191-21-018763 · doc4.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By TAS Partners LLC Disclosed balance after: 475,019 F1 · ownership.nature: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares. Read SEC document
October 23, 2020 Filed Oct 23, 2020 21:12 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	994,488	$2.71	$2,699,736.57	Disclosure SEC source: 0001453687-20-000116 · wf-form4_160348753569456.xml · nonDerivative · entry 3 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 14,480,948 F4 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $2.64 to $2.80. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
October 22, 2020 Filed Oct 23, 2020 21:12 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	1,770,204	$2.63	$4,656,698.64	Disclosure SEC source: 0001453687-20-000116 · wf-form4_160348753569456.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 13,486,460 F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $2.5389 to $2.70. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
October 21, 2020 Filed Oct 23, 2020 21:12 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	880,000	$2.50	$2,199,472.00	Disclosure SEC source: 0001453687-20-000116 · wf-form4_160348753569456.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 11,716,256 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $2.26 to $2.60. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
October 20, 2020 Filed Oct 20, 2020 22:07 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	910,000	$2.21	$2,013,193.00	Disclosure SEC source: 0001453687-20-000114 · wf-form4_160323163044460.xml · nonDerivative · entry 3 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,836,256 F4 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $2.17 to $2.30. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
October 19, 2020 Filed Oct 20, 2020 22:07 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	759,500	$2.36	$1,795,002.30	Disclosure SEC source: 0001453687-20-000114 · wf-form4_160323163044460.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,926,256 F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $2.225 to $2.50. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
October 16, 2020 Filed Oct 20, 2020 22:07 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	218,196	$2.42	$528,034.32	Disclosure SEC source: 0001453687-20-000114 · wf-form4_160323163044460.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,166,756 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $2.34 to $2.4992. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
October 09, 2020 Filed Oct 14, 2020 20:18 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	276,703	$2.00	$552,465.21	Disclosure SEC source: 0001453687-20-000112 · wf-form4_160270671386539.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,948,560 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $1.985 to $2.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
October 08, 2020 Filed Oct 8, 2020 21:50 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	530,441	$1.89	$1,000,836.08	Disclosure SEC source: 0001453687-20-000110 · wf-form4_160219382314281.xml · nonDerivative · entry 3 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,671,857 F4 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $1.799 to $1.90. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
October 07, 2020 Filed Oct 8, 2020 21:50 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	654,953	$1.65	$1,078,576.60	Disclosure SEC source: 0001453687-20-000110 · wf-form4_160219382314281.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,141,416 F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $1.55 to $1.70. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
October 06, 2020 Filed Oct 8, 2020 21:50 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	2,000,000	$1.68	$3,365,800.00	Disclosure SEC source: 0001453687-20-000110 · wf-form4_160219382314281.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,486,463 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $1.605 to $1.70. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
June 19, 2020 Filed Jun 23, 2020 20:47 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $3.00	$0.00	Disclosure SEC source: 0001453687-20-000079 · wf-form4_159294525664037.xml · derivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-06-18 F1 · derivative.exercise_date: The option vests in full on the earlier of June 19, 2021 or the day immediately prior to the company's 2021 annual meeting of stockholders. Read SEC document
June 18, 2020 Filed Jun 19, 2020 22:17 UTC	Morphic Holding, Inc. MORF · Entity 88114	GrantDirector Stock Option (right to buy) · Derivative	12,000	$0.00 Strike: $22.96	$0.00	Disclosure SEC source: 0001209191-20-038046 · doc4.xml · derivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-06-18 F1 · derivative.exercise_date: The option will vest in full on June 18, 2021, subject to the reporting person's provision of service to the issuer on the vesting date. Read SEC document
December 23, 2019 Filed Dec 26, 2019 22:30 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	GrantWarrants · Derivative	1,970,443	$0.13 Strike: $1.46	$246,305.38	Disclosure SEC source: 0001104659-19-076222 · a4.xml · derivative · entry 4 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,970,443 Underlying: Common Stock · 1,970,443 shares Expires 2024-12-23 F1 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
December 23, 2019 Filed Dec 26, 2019 22:30 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	GrantCommon Stock	3,940,887	$1.46	$5,753,695.02	Disclosure SEC source: 0001104659-19-076222 · a4.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,486,463 F1 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
December 12, 2019 Filed Dec 17, 2019 00:56 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	OtherCommon Stock	1,237,028	$0.00	$0.00	Disclosure SEC source: 0001453687-19-000171 · edgar.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,293,625 F1 · kind: On December 12, 2019, the Springer Charitable Trust (the "Trust"), a charitable remainder trust to which the reporting person is a beneficiary, made a distribution to the reporting person of 1,237,028 shares of the issuer's common stock in partial satisfaction of the Trust's obligation to pay the reporting person the remainder of the assets of the Trust and in connection with the anticipated termination of the Trust. Read SEC document
December 10, 2019 Filed Dec 12, 2019 23:36 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	GiftCommon Stock	296,000	$0.00	$0.00	Disclosure SEC source: 0000899243-19-029093 · doc4.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,376,567 F1 · shares: Represents shares of the Company's common stock transfered as a gift for no consideration to the Institute of Protein Innovation, a not-for-profit research institution. Read SEC document
December 05, 2019 Filed Dec 9, 2019 22:45 UTC	Morphic Holding, Inc. MORF · Entity 88114	GrantStock Option (right to buy Common Stock) · Derivative	90,000	$0.00 Strike: $15.72	$0.00	Disclosure SEC source: 0001179110-19-012547 · edgar.xml · derivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2029-12-05 F1 · derivative.exercise_date: 25% of the shares vest on December 15, 2020 and then 9.375% vest quarterly thereafter, with 100% of the option vested and exercisable on December 15, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document
September 03, 2019 Filed Sep 6, 2019 01:48 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	OtherCommon Stock	1,237,028	$0.00	$0.00	Disclosure SEC source: 0001453687-19-000138 · edgar.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 F1 · kind: Reflects a liquidating distribution by Leukon Investments, LP to its partners. F2 · ownership.nature: Held by Leukon Investments, LP. F4 · ownership.nature: LKST, Inc. is the general partner of Leukon Investments, LP. Timothy Springer is the president of LKST, Inc. and the managing member of TAS Partners LLC. The Reporting Person disclaims beneficial ownership of the securities held by Leukon Investments, LP and TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
September 03, 2019 Filed Sep 6, 2019 01:08 UTC	Scholar Rock Holding Corp SELB · Entity 3721	OtherCommon Stock	1,237,028	$0.00	$0.00	Disclosure SEC source: 0001453687-19-000136 · edgar.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 F1 · kind: Reflects a liquidating distribution by Leukon Investments, LP to its partners. F2 · ownership.nature: Held by Leukon Investments, LP. F4 · ownership.nature: LKST, Inc. is the general partner of Leukon Investments, LP. Timothy Springer is the president of LKST, Inc. and the managing member of TAS Partners LLC. The Reporting Person disclaims beneficial ownership of the securities held by Leukon Investments, LP and TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
August 20, 2019 Filed Aug 20, 2019 20:33 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	GrantCommon Stock	1,100,000	$1.81	$1,991,000.00	Disclosure SEC source: 0001453687-19-000126 · wf-form4_156633317611747.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,545,576 F1 · ownership.nature: LKST, Inc. is the general partner of Leukon Investments LP. Timothy Springer is the president of LKST, Inc. and the managing member of TAS Partners, LLC. The Reporting Person disclaims beneficial ownership of the securities held by Leukon Investments LP and TAS Partners, LLC except to the extent of his pecuniary interest therein, if any. F2 · ownership.nature: Held by TAS Partners, LLC Read SEC document
August 20, 2019 Filed Aug 20, 2019 20:33 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	GrantCommon Stock	1,600,000	$1.81	$2,896,000.00	Disclosure SEC source: 0001453687-19-000126 · wf-form4_156633317611747.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,056,597 Read SEC document
August 19, 2019 Filed Aug 21, 2019 22:57 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	GiftCommon Stock	296,000	$0.00	$0.00	Disclosure SEC source: 0001104659-19-046846 · a4.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,672,567 F1 · shares: Represents shares of the Company's common stock transfered as a gift for no consideration to the Institute of Protein Innovation, a not-for-profit research institution. Read SEC document
August 14, 2019 Filed Aug 16, 2019 20:18 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	10,000	$1.74	$17,415.00	Disclosure SEC source: 0001453687-19-000112 · wf-form4_156598667111543.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 86,418 F1 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.69 to $1.75. The Reporting Person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
July 01, 2019 Filed Jul 1, 2019 23:21 UTC	Morphic Holding, Inc. MORF · Entity 88114	ConversionSeries Seed Preferred Stock · Derivative	341,686	$0.00	$0.00	Disclosure SEC source: 0001179110-19-008260 · edgar.xml · derivative · entry 11 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By TAS Partners LLC Disclosed balance after: 0 Underlying: Common Stock · 341,686 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series Seed Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.exercise_date: Each share of the issuer's Series Seed Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.expiration_date: Each share of the issuer's Series Seed Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F4 · ownership.nature: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares. Read SEC document
July 01, 2019 Filed Jul 1, 2019 23:21 UTC	Morphic Holding, Inc. MORF · Entity 88114	ConversionSeries B Preferred Stock · Derivative	1,345,569	$0.00	$0.00	Disclosure SEC source: 0001179110-19-008260 · edgar.xml · derivative · entry 10 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,345,569 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of the issuer's Series B Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.exercise_date: Each share of the issuer's Series B Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.expiration_date: Each share of the issuer's Series B Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. Read SEC document
July 01, 2019 Filed Jul 1, 2019 23:21 UTC	Morphic Holding, Inc. MORF · Entity 88114	ConversionSeries A Preferred Stock · Derivative	2,286,588	$0.00	$0.00	Disclosure SEC source: 0001179110-19-008260 · edgar.xml · derivative · entry 9 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,286,588 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. Read SEC document
July 01, 2019 Filed Jul 1, 2019 23:21 UTC	Morphic Holding, Inc. MORF · Entity 88114	ConversionSeries Seed Preferred Stock · Derivative	332,805	$0.00	$0.00	Disclosure SEC source: 0001179110-19-008260 · edgar.xml · derivative · entry 8 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 332,805 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series Seed Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.exercise_date: Each share of the issuer's Series Seed Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.expiration_date: Each share of the issuer's Series Seed Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. Read SEC document
July 01, 2019 Filed Jul 1, 2019 23:21 UTC	Morphic Holding, Inc. MORF · Entity 88114	PurchaseCommon Stock	33,333	$15.00	$499,995.00	Disclosure SEC source: 0001179110-19-008260 · edgar.xml · nonDerivative · entry 5 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By TAS Partners LLC Disclosed balance after: 375,019 F4 · ownership.nature: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares. Read SEC document
July 01, 2019 Filed Jul 1, 2019 23:21 UTC	Morphic Holding, Inc. MORF · Entity 88114	ConversionCommon Stock	341,686	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-19-008260 · edgar.xml · nonDerivative · entry 4 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By TAS Partners LLC Disclosed balance after: 341,686 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the issuer's Series Seed Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F4 · ownership.nature: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares. Read SEC document
July 01, 2019 Filed Jul 1, 2019 23:21 UTC	Morphic Holding, Inc. MORF · Entity 88114	ConversionCommon Stock	1,345,569	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-19-008260 · edgar.xml · nonDerivative · entry 3 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,565,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of the issuer's Series B Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. Read SEC document
July 01, 2019 Filed Jul 1, 2019 23:21 UTC	Morphic Holding, Inc. MORF · Entity 88114	ConversionCommon Stock	2,286,588	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-19-008260 · edgar.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,219,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the issuer's Series A Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. Read SEC document
July 01, 2019 Filed Jul 1, 2019 23:21 UTC	Morphic Holding, Inc. MORF · Entity 88114	ConversionCommon Stock	332,805	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-19-008260 · edgar.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 933,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the issuer's Series Seed Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. Read SEC document
June 14, 2019 Filed Jun 18, 2019 20:22 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $2.10	$0.00	Disclosure SEC source: 0001453687-19-000074 · wf-form4_156088932766321.xml · derivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-13 F1 · derivative.exercise_date: The option vests in full on the earlier of June 14, 2020 or the day immediately prior to the company's 2020 annual meeting of stockholders. Read SEC document
January 25, 2019 Filed Mar 29, 2019 20:15 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	66,666	$1.50	$99,999.00	Disclosure SEC source: 0001055624-19-000002 · wf-form4_155389051295591.xml · nonDerivative · entry 3 SPRINGER TIMOTHY A · CIK 0001055624 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 76,418 Read SEC document
January 25, 2019 Filed Mar 29, 2019 20:15 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	4,000,000	$1.50	$6,000,000.00	Disclosure SEC source: 0001055624-19-000002 · wf-form4_155389051295591.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,456,597 Read SEC document
June 22, 2018 Filed Jun 26, 2018 21:34 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	GrantStock Option (right to buy) · Derivative	20,316	$0.00 Strike: $21.62	$0.00	Disclosure SEC source: 0001104659-18-042345 · a4.xml · derivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,316 Underlying: Common Stock · 20,316 shares Expires 2028-06-22 F1 · derivative.exercise_date: This option vests monthly over three (3) years, with the first monthly amount vesting on June 29, 2018. Read SEC document
June 15, 2018 Filed Jun 19, 2018 23:02 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $12.75	$0.00	Disclosure SEC source: 0001638599-18-000671 · doc4_5487.xml · derivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-14 F1 · derivative.exercise_date: The option vests in full on the earlier of June 15, 2019 or the day immediately prior to the company's 2019 annual meeting of shareholders. Read SEC document
May 29, 2018 Filed Jun 1, 2018 01:41 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	ConversionSeries A-4 Preferred · Derivative	787,649	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-037312 · a4.xml · derivative · entry 13 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By TAS Partners, LLC Disclosed balance after: 0 Underlying: Common Stock · 275,903 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F1 · price: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F2 · ownership.nature: Timothy Springer is the Managing Member of TAS Partners, LLC. Read SEC document
May 29, 2018 Filed Jun 1, 2018 01:41 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	ConversionSeries C Preferred · Derivative	855,391	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-037312 · a4.xml · derivative · entry 12 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 299,632 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F1 · price: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.